Brief: AB Science Says Phase 2B/3 Study Evaluating Masitinib In Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Met Primary Endpoint
29/04/2021 18:09
April 29 (Reuters) - AB SCIENCE SA ABS.PA :
* PHASE 2B/3 STUDY EVALUATING MASITINIB IN IN METASTATIC
CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) MET ITS PRIMARY
ENDPOINT
Source text for Eikon: ID:nGNE9G8v9R
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041